Previous Next

ARCHIVE

№2' 2019

OPHTHALMOLOGY

International Medical Journal, Vol. 25., Iss. 2, 2019, P. 62−64.


ENCAD-BIOLIK EFFECTIVENESS IN TREATMENT OF PIGMENTED RETINAL ABIOTROPHY


Miroshnik D. M.

Municipal Non−Profit Organization Kharkiv Regional Council "Regional Clinical Hospital", Kharkiv, Ukraine

The problem of stabilization of visual functions of patients with various forms of retinal abiotrophy remains relevant and not fully resolved. To study the effectiveness of the use of the drug "Encad−Biolik" in the combined therapy of retinal pigment abiotrophy, a study of the results of treatment of 30 (60 eyes) patients with this pathology was conducted. The drug "Encad−Biolik" was used in a combined therapy in the form of intramuscular injections of 5.0 ml 1 time per day and subconjunctivally with 10.5 mg for 10−15 days. Treatment efficacy was assessed at 6, 12, and 18 months. According to the results of observations after the use of the drug "Encad−Biolik" in a combined therapy in patients of the main group, in contrast to the control group, the fields of vision and stability of light sensitivity were increased. There was a significant difference (p < 0.05) in the stabilization of peripheral vision too. It should be noted that there were no adverse reactions when using this drug. Four patients after subconjunctival injections had painful sensations, probably related to the peculiarities of the pain threshold. In these cases, in addition to instillation anesthesia with proparacaine, the application with a cotton swab with the same preparation for three minutes was successfully used. The results of the study lead to the following conclusions: the use of the drug "Encad−Biolik" in patients with retinal pigment abiotrophy makes it possible to stabilize the pathological process and visual functions; the drug helps to reduce the frequency of such complications of retinitis pigmentosa, such as the development of atrophic changes in the macular area of retina; the use of this drug is safe, its effectiveness is noted after the second course of treatment, and the most pronounced positive changes occur since the third course.

Key words: retinal pigment abiotrophy, Encad−Biolik drug, combined therapy.


Go on Top